%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D9%87%D9%86%D8%AA%D8%B1Category:Hunter_syndromeMorbus_HunterHunter_syndromeS%C3%ADndrome_de_Hunter%D8%A8%DB%8C%D9%85%D8%A7%D8%B1%DB%8C_%D9%87%D8%A7%D9%86%D8%AA%D8%B1Maladie_de_Hunter%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%94%D7%90%D7%A0%D7%98%D7%A8Sindrome_di_Hunter%D0%93%D1%83%D0%BD%D1%82%D0%B5%D1%80_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC%D1%8BSindrom_HunterSyndroom_van_HunterS%C3%ADndrome_de_HunterSindromul_Hunter%D0%91%D0%BE%D0%BB%D0%B5%D0%B7%D0%BD%D1%8C_%D0%A5%D0%B0%D0%BD%D1%82%D0%B5%D1%80%D0%B0%D0%A5%D0%B0%D0%BD%D1%82%D0%B5%D1%80%D0%BE%D0%B2_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BCHunters_sjukdomHunter_sendromuQ1529983
about
sameAs
Parental Coping With Challenging Behavior in Mucopolysaccharidosis Type I-IIIStudy to Evaluate the Safety and Efficacy of Adalimumab in MPS I and IIExtension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive ImpairmentCollection and Study of Cerebrospinal Fluid in Patients With Hunter SyndromeAn Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis IIA Study of JR-141 in Patients With Mucopolysaccharidosis IIRGX-121 Gene Therapy in Patients With MPS II (Hunter Syndrome)Biomarker for Hunter DiseaseA Study of GC1111 in Hunter Syndrom PatientsLong-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of AgeObservational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersTo Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome PatientsSafety and Efficacy of HunteraseA Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive ImpairmentA Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) PatientsStudy of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VISafety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter SyndromeLysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool ChildrenStudy to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia ClinicsScreening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome PatientsAllogeneic Bone Marrow Transplant for Inherited Metabolic DisordersClinical Trial of Growth Hormone in MPS I, II, and VISafety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase TherapyMucopolysaccharidosis Type II Natural HistoryHunter Outcome Survey (HOS)UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like CellsMT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisLongitudinal Studies of Brain Structure and Function in MPS DisordersExtension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving IdursulfaseStudy of Idursulfase-beta (GC1111) in Hunter SyndromeIduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)A Study of JR-141 in Patients With Mucopolysaccharidosis Type IIPhase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)A Study of Potential Treatment-Responsive Biomarkers in Hunter SyndromeIntensive Pharmacovigilance Program for Elaprase (SHP ELA-701)
P1050
P2175
P2293
P4044
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyTen years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensusDevelopment of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive ImpairmentReduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
P921
Q61909222-43F4B9E1-7A5C-4003-B0FC-1D6E8B9DCD1BQ61909831-A2958A91-A5E7-45FF-91ED-D723BE54E35EQ61956992-9DB3F19F-1D16-4510-BCCE-2EBEF113B896Q61967626-1152DAB7-1904-4619-8C15-F9A0EDC0ABE1Q62042351-BCD9C6E4-9657-4A88-87A2-715C50E8709FQ63397775-948C8170-E5AC-4C81-B122-5C19286FE11DQ63398337-9025F746-63CF-4C95-B215-893978FA9EDDQ63572838-C6C1ED84-19B1-44ED-929D-9305CD33F7C8Q63573519-2C311CBB-A5EA-4CC9-B731-D225420CEF89Q63590436-699A97BE-0F03-4E58-AA6F-5D9976468E90Q63590928-16F7E89F-DB2F-4FF8-BD85-9E62B8E54ADBQ63812962-269DE953-BD74-4528-A30E-48824FB94643Q63814026-E73A474D-3FE7-468B-A43D-3A452D681C9BQ63840652-0A6DA743-2DD6-4D9E-B328-A12E61C8F8A6Q63843763-2B100CA4-C7F4-4FAA-AE35-D41B31B59BC2Q64123465-57FE6FD0-3DE1-455A-AA82-98B246E35503Q64123668-7F3BD04E-4335-4248-9B79-58F07D654B30Q64348640-3A75ED96-5D30-4214-8E77-E4E078BBC2A4Q64396737-A283EF1A-607C-43B0-A241-C0BEB3892871Q64397300-B8052132-6BCF-4922-9AFA-545B384610F2Q64606490-465BD223-D055-4E5F-A68F-F3D7480BC954Q64612588-A92D400D-B291-4B73-AFAD-D2B0DE1B428EQ64642990-BB37F09E-1339-4773-9024-07B783DC5476Q64673109-8229155B-28DC-4F90-8A6B-12D4BDB78E89Q64679466-77CA5F7A-56D3-4E6A-8078-B3771E106EC8Q64683748-D075D3AB-4F32-403B-92EE-DE34A43A028BQ64716896-0639F496-9840-461E-9839-EABBEB1CE92AQ64724866-83D627DE-B960-4097-AD7B-70CE95521A9EQ64801239-03C27936-09BF-44C1-A0D4-EF66A9AAFB64Q64817010-E3DDBF32-B786-4041-8CEB-753980E12ADAQ65351810-7888FEE5-3D51-4944-9FA0-67C7971C12E5Q65354328-F598EC0D-8939-4E71-988C-93078C05F961Q65364187-CFE63BAE-E201-42C7-A067-7F7D48BC7EFFQ65378377-310EF51E-D855-4968-AE57-C105E18632E5Q65465855-E395C116-B183-4F3B-BE94-E54FCD0EDD3BQ66034690-D55437B2-EB37-4842-9D59-CE68E5BC123FQ66044866-FB68568E-FF12-42B2-8B2B-7AE7254EDE46Q66061909-E789E380-A307-431B-9E8B-E089A819D64BQ66063438-542A9F51-0020-485D-803E-9D5C9A028660Q66066579-F8DF1731-4B2A-4AE1-B90F-7F43B4F4216C
P1050
description
Krankheit
@de
maladie génétique dégénérative lysosomale, mucopolysaccharidose de type II.
@fr
mucopolysaccharidosis characte ...... mal enzyme iduronate sulfatase
@en
tipologia di mucopolisaccarido ...... lattie da accumulo lisosomiale
@it
name
Hunter sendromu
@tr
Hunter syndrome
@hi
Hunters sjukdom
@sv
Morbus Hunter
@de
Sindrom Hunter
@ms
Sindromul Hunter
@ro
Syndroom van Hunter
@nl
Síndrome de Hunter
@es
maladie de Hunter
@fr
mucopolysaccharidosis II
@en
type
label
Hunter sendromu
@tr
Hunter syndrome
@hi
Hunters sjukdom
@sv
Morbus Hunter
@de
Sindrom Hunter
@ms
Sindromul Hunter
@ro
Syndroom van Hunter
@nl
Síndrome de Hunter
@es
maladie de Hunter
@fr
mucopolysaccharidosis II
@en
altLabel
Hunter syndrome
@en
Hunter's syndrome
@en
Hunter症候群
@ja
Ids Deficiency
@en
Iduronate 2-Sulfatase Deficiency
@en
MPS II - Hunter syndrome
@en
MPS II
@en
MPS2
@en
MPSII
@en
MUCOPOLYSACCHARIDOSIS, TYPE II
@en
prefLabel
Hunter sendromu
@tr
Hunter syndrome
@hi
Hunters sjukdom
@sv
Morbus Hunter
@de
Sindrom Hunter
@ms
Sindromul Hunter
@ro
Syndroom van Hunter
@nl
Síndrome de Hunter
@es
maladie de Hunter
@fr
mucopolysaccharidosis II
@en
P279
P2888
P2892
P31
P672
P486
P646
P672
P1199
P1417
science/Hunter-syndrome
P1461
hunters-syndrome